Analysts See $-0.13 EPS for VIVUS, Inc. (VVUS)

February 24, 2018 - By Dolores Ford

 Analysts See $ 0.13 EPS for VIVUS, Inc. (VVUS)
Investors sentiment decreased to 0.53 in Q3 2017. Its down 0.74, from 1.27 in 2017Q2. It dropped, as 12 investors sold VIVUS, Inc. shares while 22 reduced holdings. 5 funds opened positions while 13 raised stakes. 32.65 million shares or 13.20% less from 37.61 million shares in 2017Q2 were reported.
Moreover, Plante Moran Fin Advsr Ltd has 0% invested in VIVUS, Inc. (NASDAQ:VVUS). Sg Americas Secs Ltd Limited Liability Company reported 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Bancorporation Of America Corporation De invested 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Tortoise Ltd Limited Liability Company has 0% invested in VIVUS, Inc. (NASDAQ:VVUS). Commercial Bank Of New York Mellon reported 102,414 shares. Menta Capital Limited Liability reported 156,421 shares stake. Switzerland-based Credit Suisse Ag has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Grp Incorporated One Trading Limited Partnership stated it has 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Wells Fargo & Communications Mn invested in 0% or 36,964 shares. Benjamin F Edwards And Communications Incorporated has 0% invested in VIVUS, Inc. (NASDAQ:VVUS). 2.96M are held by Acadian Asset Ltd Liability. Deutsche Financial Bank Ag invested in 2.39 million shares. Hanson Mcclain holds 250 shares. Goldman Sachs Inc accumulated 123,811 shares. Susquehanna Grp Inc Llp accumulated 116,676 shares.

Analysts expect VIVUS, Inc. (NASDAQ:VVUS) to report $-0.13 EPS on March, 14.They anticipate $0.67 EPS change or 124.07 % from last quarter’s $0.54 EPS. After having $-0.06 EPS previously, VIVUS, Inc.’s analysts see 116.67 % EPS growth. The stock decreased 1.81% or $0.0086 during the last trading session, reaching $0.4663. About 266,129 shares traded. VIVUS, Inc. (NASDAQ:VVUS) has declined 7.14% since February 24, 2017 and is downtrending. It has underperformed by 23.84% the S&P500.

VIVUS, Inc. (NASDAQ:VVUS) Ratings Coverage

Among 2 analysts covering Vivus (NASDAQ:VVUS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vivus had 3 analyst reports since July 31, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Outperform” rating and $4 target in Friday, July 31 report. Zacks upgraded the shares of VVUS in report on Wednesday, August 5 to “Hold” rating. WallachBeth Capital upgraded the stock to “Buy” rating in Thursday, November 5 report.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company has market cap of $49.41 million. The firm offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It has a 1.38 P/E ratio. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: